18 result(s) for 'CD8'
11 - 18 of 18 results for 'CD8'
Sort by
Show
Antigen BackgroundTIM-3 (T-cell Immunoglobulin and Mucin Domain-Containing 3, Hepatitis A Virus Cellular Receptor, HAVCR2). TIM-3 is a Type I transmembrane that can be expressed on both tumour and immune cells. It is expressed on multiple immune cells, including type 1 T helper (Th1) cells, Th17 and CD8+ T cells, Tumour Infiltrating Lymphocytes, regulatory T cells (Tregs) and innate immune cells.DisclaimerTIM-3 is recommended for the detection of...
Antigen BackgroundCTLA-4, T-cell co-receptor cytotoxic T-cell antigen-4 (CTLA-4, CD152) is a critical inhibitory regulator of T-cell immunity. CTLA-4 is expressed almost exclusively on CD4+ and CD8+ T-cells and is crucial in the maintenance of T-cell homeostasis. Expression is induced on activated T-cells, with marginal expression on resting cells. The role of CTLA-4 in regulation of T-cell activity in the tumour microenvironment indicates a pote...
Antigen Background
The CD57 glycoprotein, also known as HNK-1, has a molecular weight of 110 kD. It is found on a subset of mononuclear cells with natural killer activity and on neuroectodermal cells expressing myelin-associated glycoprotein. Many cells which co-express CD57 and CD8 proteins are a subset of suppressor/cytotoxic T cells. These cells play a role in the rejection of grafts in acute graft versus host disease. The CD57 molecule is not...
DESCRIPTION: Chromogenic multiplex IHC kit for BOND RX - human CD68, CD163, PD-L1
SIZE: 10 slides
PRODUCT OVERVIEW: Kit for chromogenic multiplex IHC staining of 10 slides plus a single negative control slide on the BOND RX with V7.0 software.
1° Antibody
Clone
1° Tag
2° Antibody
Chromogen
CD8
C68/684
UT021
Anti-UT021-AP
Leica Refine Red
CD163
EPR19518
UT015
Anti-UT015-HRP
Yellow
PD-L1
73-10
UT014
Anti-UT014-HRP
Leica Blue
Leica Refin...
Introduction to immuno oncology
1. Introduction to Immuno-Oncology Michael Bates, MD Oncology Strategy, Medical and Scientific Affairs Cepheid Sunnyvale, CA Cepheid and Leica Biosystems are Danaher Companies
2. Overview • History of Immuno-Oncology • Types of Immunotherapy • Immunomodulatory agents • Personalized Cancer Vaccines • CAR-T cell therapy • Immune Checkpoint Inhibitors • Focus: Immune Checkpoint Biomarkers
3. Evolution of Cancer Immunotherapy • William Coley – 1890s surgeon • Coley’s toxin… • BCG, IFN-alpha, IL-2 • IL-2 applications in melanoma and RCC proved that advanced metastatic cancers can be controlled in some patients by stimulating T cells with cytokines • Critical development • CTLA-4 shown to be inhibitory for T cell responses by James Allison and Jeff Blu...
Biomarkers
AE1/AE3 (1)
AMACR (2)
BCL6 (1)
CD163 (2)
CD20 (2)
CD3 (9)
CD4 (5)
CD68 (5)
CD8 (10)
CDX2 (2)
CK20 (5)
Ck5 (4)
...
Slide 1
Hello, hello; thank you so much for that introduction. Let's get started. Oh, I'm sorry, I just need to hit this next button here. So my name is Mark Lawson.
Thank you for joining us in this webinar. I'm here to present BOND RX tips, tricks, and optimization. It's going to be a user guide from the BOND RX and chromogenic multiplexing in the research application.
Slide 2
So, my name is Mark Lawson. I'm an application specialist on the Life Sciences team at Leica Biosystems I provide technical support for the Life Sciences portfolio, including but not limited to the BOND RX, the BOND RXm, and a wide array of reagents. So I've worked in the histology field for about 15 years and in both clinical and research spaces. I started off as a histotechnologist and worked my way up...
The potential for non-invasive tests that provide equivalent research and diagnostic value as can be obtained from tissue biopsies is real, but not yet realized. Tissue biopsies allow for identification, phenotyping and molecular analysis of cancer and...